toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
  Record Links
Author Bisgaard, H. url  openurl
  Title Role of leukotrienes in asthma pathophysiology Type Journal Article
  Year (down) 2000 Publication Pediatric Pulmonology Abbreviated Journal Pediatr Pulmonol  
  Volume 30 Issue 2 Pages 166-176  
  Keywords Adrenal Cortex Hormones/pharmacology; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use; Asthma/drug therapy/*physiopathology; Bronchial Hyperreactivity/physiopathology; Cysteine/*physiology; Humans; Inflammation Mediators/*physiology; Leukotriene Antagonists/therapeutic use; Leukotrienes/*physiology; Receptors, Leukotriene/*physiology  
  Abstract Inflammation is an essential component of asthma pathophysiology. While beta(2)-agonists are often used for short-term relief of acute bronchospasm, anti-inflammatory agents are required for the long-term management of chronic inflammation in this disease. Corticosteroids have emerged as the first-line anti-inflammatory therapy for asthma management. However, in some patients, especially children, the high doses of corticosteroids that may be required to control features of hyperresponsiveness, including exercise-induced asthma, raise safety concerns. Thus, there is a need for complementary anti-inflammatory, steroid-sparing agents in asthma therapy. Several inflammatory mediators have been targeted in an attempt to thwart this inflammatory process, but so far with little success. The cysteinyl leukotrienes (CysLT), LTC(4), LTD(4), and LTE(4), have been shown to be essential mediators in asthma, making them obvious targets for therapy. These cysteinyl leukotrienes, previously known as the slow-reacting substance of anaphylaxis (SRS-A), mediate many of the features of asthma, including bronchial constriction, bronchial hyperreactivity, edema, and eosinophilia. Data show that selective cysteinyl leukotriene receptor antagonists (CysLTRAs) effectively reverse these pathologic changes. Corticosteroids do not inhibit the production of CysLTs in vivo, suggesting that CysLTRAs and corticosteroids affect different targets. The bronchodilator properties of CysLTRAs seem to be additive to those of beta(2)-agonists and corticosteroids. These data suggest that CysLTs are important therapeutic targets in the management of inflammation in asthma.  
  Address Department of Pediatrics, National University Hospital, Rigshospitalet, Copenhagen, Denmark. Bisgaard@RH.DK  
  Corporate Author Thesis  
  Impact Factor 02,704 First Author Bisgaard, H. Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Senior Author Bisgaard, H.  
  ISSN 1099-0496 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:10922142 Approved no  
  Call Number Serial 223  
Permanent link to this record
Select All    Deselect All
 |   | 

Save Citations:
Export Records: